Open an account

CalciMedica

CALC · NASDAQ

$1.07+$0.045 (+4.41%)TodayMarket closed ·
Prev close $1.02

About CALC

CalciMedica, Inc. is a clinical-stage biopharmaceutical company, which engages in developing therapies for life-threatening inflammatory diseases. The company is headquartered in La Jolla, California and currently employs 16 full-time employees. The company went IPO on 2020-09-25. The firm focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for inflammatory and immunologic diseases. The firm's technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury. Its lead product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The firm is conducting a Phase IIb trial (called CARPO) for acute pancreatitis (AP) with systemic inflammatory response syndrome (SIRS), as well as supporting the ongoing Phase I/II asparaginase-induced pancreatic toxicity (AIPT) study (called CRSPA).

Employees
16
Headquarters
La Jolla, California
Listed
Sep 25, 2020
Sector
Health Care
Industry
Pharmaceuticals
Website
calcimedica.com

CALC key statistics

Market cap
7.27M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
60.74K
Volume
42.85K
Open price
$1.03
High today
$1.10
Low today
$1.02
52 Week high
$36.00
52 Week low
$1.00

CalciMedica (CALC) at a glance

CalciMedica (CALC) last traded at $1.07, with a market cap of 7.27M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $1.02 and $1.10. The current price is 4.4% above the day's low and 3.2% below its high.

Volume so far is 42.85K shares, below the average of 60.74K shares a day.

Over the past year CalciMedica has ranged from $1.00 to $36.00, and now sits 0% of the way up that range.

CalciMedica met or beat analyst EPS estimates in 2 of the last 8 quarters. In Q2 FY26 it reported -$2.25 per share against an estimate of -$1.45.

The average analyst price target is $38.25, 3491.5% above the current price, from 3 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

67%of 3 analyst ratings say Buy
  • Buy66.7%
  • Hold33.3%
  • Sell0.0%
Price target · 4 analystsAvg $38.25
Low
$30.30
Now
$1.07
High
$47.25

CALC earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 2 of the last 8 quarters, by 103.2% on average.

  1. Q3 FY24: reported -$2.50 per share against an estimate of -$2.53
  2. Q4 FY24: reported -$1.90 per share against an estimate of -$1.80
  3. Q1 FY25: reported -$1.80 per share against an estimate of -$1.56
  4. Q2 FY25: reported -$2.00 per share against an estimate of -$1.78
  5. Q3 FY25: reported -$2.60 per share against an estimate of -$2.10
  6. Q4 FY25: reported -$3.65 per share against an estimate of -$2.10
  7. Q1 FY26: reported $1.50 per share against an estimate of -$1.43
  8. Q2 FY26: reported -$2.25 per share against an estimate of -$1.45

CALC news

  • 12 Health Care Stocks Moving In Monday's After-Market Session

  • Press releasePRNewswire

    CalciMedica Announces FDA Alignment on Phase 2b Trial Design for Auxora in Acute Pancreatitis and Identifies Disease's First Potential Registrational Endpoints

  • 12 Health Care Stocks Moving In Friday's Intraday Session

  • Vandana Singh

    FDA Raises No Concerns Over Auxora Safety Data, CalciMedica Advances Trial

  • Market-Moving News for June 24th

  • Press releasePRNewswire

    CalciMedica Announces Private Placement Financing for Up to Approximately $49 Million to Advance Pulmonary Hypertension Program

  • Press releasePRNewswire

    CalciMedica Announces Clinical Development of Auxora May Proceed Following FDA Review of KOURAGE Trial Interim Safety Data

  • Press releasePRNewswire

    CalciMedica Reports First Quarter 2026 Financial Results and Provides Clinical & Corporate Updates

Similar companies

Companies in the same industry as CalciMedica

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.